Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations

Jingjing Zhang, Lili Ding, Baocan Wang, Gaiyan Ren, Aning Sun, Chao Deng, Xiaohui Wei, Sridhar Mani, Zhengtao Wang, Wei Dou

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, I κB a, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/ C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis inmice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.

Original languageEnglish (US)
Article numberA9
Pages (from-to)315-324
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume352
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Inflammatory Bowel Diseases
Xenobiotics
Colitis
Colon
Panax notoginseng
Trinitrobenzenes
Ligands
Gene Expression
Fluorescence Resonance Energy Transfer
Dextran Sulfate
Competitive Binding
Sulfonic Acids
pregnane X receptor
notoginsenoside R1
Luciferases
Small Interfering RNA
Peroxidase
Anti-Inflammatory Agents
Phosphotransferases
Up-Regulation

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations. / Zhang, Jingjing; Ding, Lili; Wang, Baocan; Ren, Gaiyan; Sun, Aning; Deng, Chao; Wei, Xiaohui; Mani, Sridhar; Wang, Zhengtao; Dou, Wei.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 352, No. 2, A9, 01.01.2015, p. 315-324.

Research output: Contribution to journalArticle

Zhang, Jingjing ; Ding, Lili ; Wang, Baocan ; Ren, Gaiyan ; Sun, Aning ; Deng, Chao ; Wei, Xiaohui ; Mani, Sridhar ; Wang, Zhengtao ; Dou, Wei. / Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations. In: Journal of Pharmacology and Experimental Therapeutics. 2015 ; Vol. 352, No. 2. pp. 315-324.
@article{b21596a4c6514b11a79f01291f647803,
title = "Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations",
abstract = "Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, I κB a, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/ C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis inmice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.",
author = "Jingjing Zhang and Lili Ding and Baocan Wang and Gaiyan Ren and Aning Sun and Chao Deng and Xiaohui Wei and Sridhar Mani and Zhengtao Wang and Wei Dou",
year = "2015",
month = "1",
day = "1",
doi = "10.1124/jpet.114.218750",
language = "English (US)",
volume = "352",
pages = "315--324",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations

AU - Zhang, Jingjing

AU - Ding, Lili

AU - Wang, Baocan

AU - Ren, Gaiyan

AU - Sun, Aning

AU - Deng, Chao

AU - Wei, Xiaohui

AU - Mani, Sridhar

AU - Wang, Zhengtao

AU - Dou, Wei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, I κB a, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/ C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis inmice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.

AB - Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, I κB a, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/ C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis inmice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.

UR - http://www.scopus.com/inward/record.url?scp=84919708991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919708991&partnerID=8YFLogxK

U2 - 10.1124/jpet.114.218750

DO - 10.1124/jpet.114.218750

M3 - Article

VL - 352

SP - 315

EP - 324

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

M1 - A9

ER -